COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04355676

Dayana Michel

Jatin Shah, jshah@karyopharm.com (PI email not reported)

2020-04-21

Withdrawn

RCT

Randomized

Parallel

Open label

multi-center

Treatment

inclusion criteria: confirmed laboratory diagnosis of sars-cov2 by standard approved reverse transcription polymerase chain reaction (rt-pcr) assay or equivalent approved testing (by local labs). currently hospitalized and consented within the first 48 hours of hospitalization. informed consent provided as above (patients must be dosed with study drug within 12 hours of consent). has symptoms of moderate or severe covid-19 as demonstrated by: moderate covid-19: currently hospitalized and requiring medical care for covid-19, and peripheral capillary oxygen saturation (spo2, pulse oximetry) > 94% on room air at screening, and radiographic evidence of pulmonary infiltrates severe covid-19: at least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress and clinical signs indicative of lower respiratory infection with covid-19, with at least one of the following: respiratory rate ≥ 30 breaths/minute (min), heart rate ≥ 125/min, oxygen saturation (spo2) <93% on room air or requires > 2l/minute oxygen by nc in order to maintain sao2 ≥93%, pao2/fio2 <300 millimeter per mercury (mm/hg) female patients of childbearing potential must have a negative serum pregnancy test at screening and must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment. males who are sexually active must commit to use a highly effective method of contraception while receiving selinexor and for 3 months after the last selinexor dose, or consent to total sexual abstinence (abstinence must occur from enrollment and continue for 3 months after the last selinexor dose).

evidence of critical covid-19 based on: respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations) septic shock (defined by sbp < 90 mm hg, or diastolic bp < 60 mm hg) multiple organ dysfunction/failure in the opinion of the investigator, unlikely to survive for at least 48 hours from screening or anticipate mechanical ventilation within 48 hours concurrent anti-viral and/or anti-inflammatory agents (e.g., biologics, hydroxychloroquine) are not permitted. inadequate hematologic parameters as indicated by the following labs: patients with severe neutropenia (anc <1,000 x 10^9/liter [l]) or thrombocytopenia (e.g., platelets <100,000 per microliter of blood) inadequate renal function as indicated by creatinine clearance (crcl) <20 milliliter per minute (ml/min) using the formula of cockcroft and gault. inadequate hepatic function defined as ast or alt > 5x the upper limit of normal or serum direct bilirubin > 2.5x the upper limit of normal. hyponatremia defined as sodium < 135 milliequivalents per liter (meq/l). in the opinion of the investigator, patients who are below their ideal body weight and would be unduly impacted by changes in their weight. unable to take oral medication when informed consent is obtained. patients with a legal guardian or who are incarcerated. pregnant and breastfeeding women.

2

Karyopharm Therapeutics Inc

18

None

None

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

0

Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale

None

Phase 2

[{"arm_notes": "40 milligram (mg) on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).", "treatment_id": 1182, "treatment_name": "Selinexor", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "20 milligram (mg) on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).", "treatment_id": 1182, "treatment_name": "Selinexor", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}]